Physician profile
Kiley Ann Stevenson
NPI 1902363716
$11,557.61
in general payments reported to CMS, 2019-2025
36 companies · $3,531 in 2025
The $3,531 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,289 · 2022: $1,231 · 2023: $3,296 · 2024: $2,210 · 2025: $3,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,500 · Education: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,500.32 |
| Education | $537.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,780.90 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lumenis Be INC | $1,777.38 | 2023 | M22 |
| Abbvie INC. | $1,609.53 | 2021-2025 | |
| Genzyme Corporation | $1,035.70 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $938.46 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $654.01 | 2021-2025 | Sotyktu |
| Lilly USA, LLC | $394.71 | 2021-2025 | Ebglyss, Taltz |
| Amgen INC. | $379.04 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $364.20 | 2022-2025 | |
| Ucb, INC. | $309.84 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $262.25 | 2021-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $243.33 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $215.93 | 2023-2025 | Ycanth |
| Galderma Laboratories, L.P. | $211.14 | 2021-2025 | Nemluvio, Aklief |
| Organon LLC | $178.93 | 2025 | Vtama, Nexplanon |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $167.06 | 2021-2025 | |
| Leo Pharma INC. | $135.47 | 2022-2025 | Adbry |
| Organogenesis INC. | $132.50 | 2021-2025 | Affinity, Puraply, Puraply Am |
| Incyte Corporation | $110.51 | 2022-2025 | Opzelura |
| Genentech USA, INC. | $99.53 | 2021-2024 | Erivedge |
| Biofrontera INC. | $72.30 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Mimedx Group, INC. | $64.33 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $64.05 | 2024-2025 | Nuzyra |
| Convatec INC. | $52.79 | 2023-2025 | |
| Almirall LLC | $49.52 | 2021-2024 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.06 | 2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $28.63 | 2021 | |
| Journey Medical Corporation | $26.78 | 2022-2024 | |
| Ortho-Clinical Diagnostics, INC. | $24.92 | 2024 | |
| Merz North America, INC. | $22.69 | 2022 | |
| Cipher Pharmaceuticals US LLC | $17.77 | 2025 | Spinosad, Natroba |
| Arcutis Biotherapeutics, INC. | $16.09 | 2025 | Zoryve |
| Krystal Biotech INC | $14.81 | 2023 | Vyjuvek |
| Dermavant Sciences, INC. | $14.70 | 2023 | Vtama |
| Boston Scientific Corporation | $13.61 | 2025 | General - Pain Management |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiley Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.